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Summary: Homozygous deficiency of aminolaevulinate dehydratase (porphobilinogen synthase, EC 4.2.1.24)
was diagnosed in a small child. The clinical presentation was unique since severe Symptoms were already
present in the neonatal period. The patient, a boy, now three-years old, had recurrent attacks of pain,
vomiting, hyponatraemia and Symptoms of polyneuropathy engaging motor functions including respiration.
The clinical course of the disease from birth on is related, äs are the results of various attempts at therapy.
The patient excreted large amounts of 5-aminolaevulinic acid and coproporphyrin and minor amounts of
porphobilinogen in the urine. Faecal excretion of coproporphyrin and harderoporphyrin was increased
äs was erythrocyte porphyrin concentration. Diagnosis was established by the finding that erythrocyte
aminolaevulinate dehydratase activity was less than 5 per cent of normal in the patient and between 26 and
51 per cent of normal in both the parents, the grandfathers and a sibling. The activity of the enzyme could
not be restored by the addition of dithiothreitol (10~3 mol/1) alone, or in combination with zinc or manganese
in varying concentrations. The enzyme Km did not differ between affected and nonaffected members of the
family.
Introduction overload of the physiologically weak third Step of
TT t . „ the pathway, and overproduction of the porphyrin
Haem, the prosthetic group of a senes of important ecursors 5-aminolaevulinic acid and porphobilin-
protem catalysts, is synthesized from succinate and ^ acute exacerbations the diseases are recog.
glycme m eight sequential enzymatic Steps, the first ̂  fe increased urfnary excretion of ̂  porphyrin
bemg the formation of 5-aminolaevulimc acid by - sors and by severe attacks of abdominal pain,
ammolaevuhnate synthase. If the activity of one of and neurological and psychiatric disturbances. The
the enzyimes in^the chain is decreased, due to inherited toms are often precipitated by exposure to
or acquired deficiency, the rate of flow in the affected drugSj ^ so,vents an(J Qther agents ^ of
part of the metabolic pathway is reduced and the accelerating the rate of haem synthesis. For these
Substrate of the defective enzyme may accumulate. reagons ̂  condkions in question are generally re.
In the mheritable disorders of acute intermittent por- ferred to as acute Qr inducible forms of pOrphyria.
phyna, variegate pO hyria and hereditary copropor-
phyria, the impairment of catalytic power and dimin- Recently, two cases of a fourth type of acute porphy-
ished rate of haem synthesis giveriseto a derepression ria have been described (1), characterized by de-
of the initial enzyme of the sequence, subsequent creased activity of aminolaevulinate dehydratase, the
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second enzyme in the metabolic chain. The patients'
Symptoms appeared after puberty and were typical of
acute hepatic porphyria. In contrast to other hepatic
porphyrias the gene defect was clinically manifest
only in what seemed to be a homozygous state. In the
present communication the clinical and biochemical
fmdings are described in a patient with aminolaevuli-
nate dehydratase porphyria, presenting with severe
Symptoms at birth.
Aminolaevulinate dehydratase (porphobilinogen syn-
thase, EC 4.2.1.24) is the second enzyme in the haem
synthetic pathway, catalysing the condensation of
two molecules 5-aminolaevulinic acid to form the
heterocyclic monopyrrol, porphobilinogen (flg. 1).
The enzyme protein is octameric, composed of appar-
ently identical subunits of a molecular weight of
about 35 000 Daltons. It is inhibited by some heavy
metals, e. g. lead, (2) which explains the elevated urine
levels of 5-aminolaevulinic acid in lead poisoning (3).
One subunit of the enzyme eontains one zinc atom
and eight sulfhydryl groüps. It is asAimed that the
lead ions replace zinc in tbe molecule, resülting in
loss of enzymatic activity by formatiön of lead inei>
captide (4). Sulfhydryl reageiits such äs glütathione,
cysteine and dithiöthreitol äs well äs zinc and
manganese ions (5) restore the activity of the enzyme
in vitro (2, 6, 7). The enzyme is inhibited by succinyl-
acetone, a compound which accumülates in heredl·-
tary tyrosinaemia (8).
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Case History
The propositus was a boy born on April 27,1983 äs the fourth
child of a 36-year-old woman, who had given birth to 3 normal
children in 1975, 1979 and 1981. She also had 4 spontaneous
abortions in gestational weeks 7 to 13. Ultrasound examination
just prior to two of the abortions showed growth-retarded
foetuses, and microscopical examinations of the abortuses
showed regressive changes in the decidua. The three healthy
children were all born at term after normal pregnancies. The
pregnancy with the patient was also uneventful. A routine
ultrasound examination in the 32nd weck showed a slightly
reduced biparietal diameter. During the pregnancy the mother
took no medications except iron, aspirin on a few occasions and
Scheriproct® suppositories for haemorrhoids. Labor started
spontaneous movements of all limbs. No grasp reflex or Moro
under epidural analgesia with bupivacain 0.25% (total dose 18
ml) combined with blockage of the pudendal nerves also with
bupivacain (total dose 20 ml). Slight depression of foetal heart
rate was noted.
Immediately after birth the patient had shallow respiration and
showed muscular hypotonia but had a normal heart rate. Even
after Ventilation with oxygen for three minutes the hypotonia
persisted. Apgar scores at l, 5 and 10 minutes were 4, 7 and 7.
Birthweight was 3990 g, length 48.5 cm and head circumference
33.5 cm.
The patient was brought to the intensive care unit for observa-
tion. On examination he had a general hypotonus but showed
spontaneous movements of all limbs. No grasp reflex or Moro
reflex could be elicited. Muscle tendon reflexes were weak or
absent. The liver was slightly enlarged. On grounds of progres-
sive respiratory insufficiency and cyanosis he was connected to
a Ventilator at the age of 20 hours. Treatment with antibiotics
(gentamicin, benzylpenicillin), phenobarbital, dexamethasone
and furosemide was started. The initial investigations, including
EEG, ultrasound of the head and abdomen, liver function
tests, serum creatinine, plasma and urine aminugrams, urinary
excretion of organic acids, mucopolysaccharides and oligosac-
charides, thyroid function tests and blood ammonia were all
within normal limits. Blood haemoglobin was 160 g/l on the
Ist day and 121 g/l on the 3rd day. The reticulocyte count was
10.5% on the 3rd day and 6.4% on the 4th day. A blood
transfusion was given. Lumbar puncture on the flrst day
showed a spinal protein concentration of 1.25 g/l and a normal
cell count. At 31/2 weeks of age spinal protein was 0.60 g/l.
EMG at 9 and 12 days revealed an absence of motor responses
in all muscles recorded, and fibrillation potentials. Sensory
neurography showed involvement also of the sensory nerves.
The Ventilator treatment had to be continued for several weeks.
During the first weeks muscular hypotonia was profound and
no liinb movements were observed. After 3 weeks spontaneous
muscular activity of the limbs slowly returned. EMG at 29 days
of age still showed signs of denervation but the motor unit
Potentials in proximal muscle groups had improved. At 5 weeks
of age the child could finally be extubated and managed without
ventilatory support. He gradually started to eat and muscular
tonus successively improved. At 8 weeks of age there were
normal Moro and abdominal wall reflexes but head control
was poor and tendon reflexes absent. The clinical improvement
continued and the patient was discharged at the age of 61 days
without a firm diagnosis. The blood haemoglobin coneentra-
tion was 115 g/l. Further blood transfusions were not needed.
At follow-up he first showed a good development of motor
skills and muscle strength. At one year of age, although still
hypotonic, he could sit steadily, roll around, move things from
one band to the other and use a fairly good pincette grasp. He
•understood some instructions and spoke a few words. At 15
months he started to crawl and at 18 months he walked unsup-
ported. His muscular tonus was then almost normal and the
muscle tendon reflexes within normal limits. EMG at 10 months
was practically nonnal. The motor unit potentials showed some
changes consistent with an old neurogenic damage. Conduction
velocities in both motor and sensory nerves were within normal
limits. Although the patient's weight gain had been acceptable
the family complained of feeding problems. The boy had fre-
quent respiratory infections with otitis media. During such
episodes he refused to eat and vomited for long periods. He
seemed to dislike all different formulae tested.
At the age of 23 months (in March 1985) the patient became
more irritable, cried at intervals and refused to eat and drink.
A progressive muscular weakness of both legs appeared. The
patient could no longer walk or even stand up on his legs which
seemed to hurt on touching. A slight tremor in the arms
was apparent when he attempted purposeful movements. On.
examination the tendon reflexes in both legs had disappeared.
X-rays of the lumbar and sacral region revealed a slight cleft
in the 5th lumbar vertebra but myelography was normal. The
agents used for anaesthesia at the myelography were pentobar-
bital, phentanyl, pancuron, atropine, neostigmine and nitrous
oxide. Spinal protein was 0.14 g/l. EMG showed a slight reduc-
tion of motor unit potentials. At this time a porphyrin meta-
bolic investigation was done (See below: "Design of the
study"). -
The patient's condition first improved without treatment but
at the beginning of May 1985 general muscular pain and
anorexia reappeared. Intravenous treatment with 10% glucose
in water (glucose: 5 g/d · kg body weight) was started. Since no
clinical improvement occurred, carbohydrate was added in the
form of Caloreen, 250 g daily through a naso-gastric tube.
Still his condition deteriorated with involvement of respiratory
function. The breathing pattern became inverted and lung X-
ray showed almost complete absence of diaphragmatic move-
ments consistent with bilateral phrenic nerve palsy. The patient
ceased moving legs and arms, probably due partly to motor
involvement, partly to the intensive pain evidently elicited by
the movements. A central venous catheter was inserted and
haematin (Panhematin, Abbott), 2mg per kg BW was given
twice daily for 6 days. No immediate effect of haematin was
seen. Other treatments included total parenteral nutrition with
a high glucose content, metoprolol to control the blood pressure
which fluctuated, but now and then rose to 140/100 mm Hg,
and continuous positive airway pressure (CPAP) to counteract
atelectasis. The blood haemoglobin concentration was nonnal
(121 g/l) but erythrocyte concentrate (5 — 8 ml/kg) was given
nevertheless on five occasions (from May 23 to June 9) in an
attempt to suppress the erythropoiesis and hence 5-aminolaevu-
linate synthase activity in the bone marrow and possibly also
to replace the missing enzyme (9). An episode of Klebsietta
septicaemia was successfully treated with cloxacillin and netil-
micin. EMG on June 7th showed no motor responses at all on
Stimulation, either in the legs or in the arms. Abundant fibrilla-
tion potentials were seen. Sensory neurography was normal.
No further impainnent of respiratory function occurred.
Slowly, over a period of weeks, he regained some muscle
strength and a normal respiratory pattern. A general muscular
atrophy especially of the legs persisted äs well äs bilateral
cöntractures of both ankle joints. Oral feeding was reinstituted,
and the patient was discharged on July 2nd.
In August 1985 the patient once again had an upper respiratory
tract infection. Another transfusion of erythrocyte concentrate
was given, but his condition became worse. As before, he
stopped eating and drinking, appeared restless, seemed to have
sore legs, arms and body, developed tremor in both arms and
had a general sick appearance. A central venous catheter was
inserted and total parenteral nutrition again started with a high
carbohydrate content. A partial blood exchange, 80 ml per kg
BW was performed and the condition seemed to stabilize but
did not improve. An acute episode of inappropriate vasopressin
secretion intervened accompanied by weight gain, and there
was a fall of serum sodium to 110 mmol/1 with simultaneous
high urine osmolarity (530 mosmol/1), but this responded to
fluid restriction. In September 1985 another blood exchange
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was performed followed by a course of Panberaatin (2 mg per
kg BW twice daily) for 6 days. No clear efifect was seen. In
October 1985 a trial with a novel haem arginate compound
(Normosang) 3 mg/kg BW for 4 days was made. This also
failed to bring about a clinical iraprovement. Since then the
patient's condition has varied with periods of deterioration
alternating with improvement. At present (April 1986) his clini-
cal Status is characterized by plantar flexion contractures of
the ankle joints and severe calf muscle atrophy. He can sit but
not stand. The band movements are impaired. Muscle pain on
movements of the extremitites seems to vary from day to day.
Speech development is delayed, but otherwise the patient does
not appear retarded. Because of anorexia and vomiting he
continues to be totally dependent on a speciaily composed
parenteral formula for his nutrition. Skin Symptoms suggestive
of cutaneous porphyria have not developed. Blood haemoglo-
bin has been 105-114 g/l after the neonatal period, which is
in the normal r nge. The reticulocyte count has varied from
0.3% to 4.4%, usually around 2%, indicating hyperhaemolysis,
which accords with a picture of a markedly increased norv
moblastic erythropoiesis in the bone marrow smear. The patient
is not transfusion-dependent and has no splenomegaly. Serum
iron was 8 μπιοΐ/ΐ, and total iron binding capacity was 52
μτηοΙ/1 in May 1985 prior to blood therapy.
Family History
The families on the mother's and father's side have been traced
back for several generations. There is no known consanguinity
(flg. 2). A neurological disorder similar to the patient's has not
been found in any other member.
7 8 9 10
Fig. 2. Pedigree of the relatives. For explanation of the numeri-
cal symbols see table l.
Experimental
Design of study
The index case, his brother, two sisters, parents and paternal
and maternal grandparents were investigated with regard to
urinary excretion of porphyrin precursors and porphyrins, con-
centration of porphyrins in faeces, erythrocyte porphyrin and
the erythrocyte enzymes, pOφhobilinogen deaminase and
aminolaevulinate dehydratase. In the case of the propositus,
urine and faeces contained increased concentrations of porphy-
rins, which were separated, identified and quantitated. The
effect on aminolaevulinate dehydratase activity of the addition
of dithiothreitol, zinc and manganese was investigated in hae-
. molysates from the propositus (no detectable original enzyme
activity), from three relatives showing 26-50 per cent normal
enzyme activity, and from two relatives showing normal enzyme
activity. Erythrocyte aminolaevulinate dehydratase kinetics
were studied in haemolysates from the parents, both showing
only 35 per cent of normal enzyme activity, and in haemolysate
from the matemal grandmother who exhibited a normal en-
zyme activity. The urine of the propositus was tested for amino-
laevulinate dehydratase Inhibitors, and the blood and urine
were analysed for lead.
The establishment of age-related reference values for
erythrocyte aminolaevulinate dehydratase activity
In order to establish reference values for erythrocyte aminolae-
vulinate dehydratase, the results from an investigation of 880
persons between 2 and 88 years were plotted against age, and
the line of regression determined (flg. 3). The individuals se^
lected for the study had been referred to the laboratory for
investigation, but found to carry n significant clinical or
biochemical evidence of a porphyrin metabolic disturbance.
It was considered that any undetected latent cases of acute
intermittent porphyria, who might be hiddeii in the material,
would not significantly bias the distribution of values. Separate
studies of cases of acute mtermittent porphyria, where the
carrier state could be established, have shown that in this
condition the distribution of erythrocyte aminolaevulinate
dehydratase activity does not deviate from normal.
Fig. 3. Relation between age and erythrocyte aminolaevulinate
dehydratase activity in normal individuals. Enzyme ac-
tivities of the patient (® ) and his relatives (© *- ©).
For explanations of the numerical symbols See table l.
Lower r nge for 50 per cent activity of the normal age^
matched average mean is indicated by the broken line.
Materials
Porphyrins used for Standards were obtained from Porphyrin
Products, Utah, USA. Ion exchange columns for purification
of porphobilinogen, 5-aminolaevulinic acid and porphyrins
prior to analysis were purchased from Βίο-Rad Laboratories,
Richmond, California, USA. Silica gel thin layer chromatogra-
phy plates used for Separation of faecal porphyrins were Con-
centration Zone Merck HPTLC-Fertigplatten Sicone Gel 60
with fluorescence indicator F254, supplied by Kebo Grave,
Stockholm, Sweden.
Methods
For the determination of erythrocyte porphobilinogen deami-
nase (uroporphyrinogen I synthase, EC 4.3.1.8) activity, the
packed red blood cell procedure'of Magnussen et al. (10) was
used. The activity of erythrocyte aminolaevulinate dehydratase
activity was determined by the Europeen Standardized Method
(11), before and after activation with dithiothreitol 10~3 mol/1
(12). The effect on the activity of the enzyme of addition of
manganese and zinc in varying concentrations was studied s
described by Chiba & Kikuchi (13). Inhibitor activity of urine,
directed against aminolaevulinate dehydratase, was investigated
by addition of undiiuted urine or urine diluted l : 5 and l : 10
with saline (0.2 ml) to an haemolysate (l ml) from a person
with normal erythrocyte enzyme activity. Enzyme activity was
determined s described above. Kinetic parameters of aminolae-
vulinate dehydratase were determined by enzyme assay (11)
usinge varying concentrations of 5-aminolaevulinic acid s sub-
strate (0. l -10 μιηοΐ/ΐ).
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5-Aminolaevulinic acid and porphobilinogen were quantitated
in urine by the method of Mauzerall & Granick (14) after
Separation by anion-cation exchange chromatography äs de-
scribed by Doss & Schmidt (16). The individual porphyrins in
urine were separated and quantitated without prior derivatiza-
tion, by high performance liquid chromatography (17) and by
use of an octadecylsilane precolumn (18). Porphyrins in faeces
were separated äs methyl esters (19) by thin layer chromatogra-
phy (20) and individually quantitated after elution from the
Chromatographie plate with a chloroform-ethanol mixture (21).
Three-carboxylated porphyrin was identified by the position in
the chromatogram between coproporphyrin and protoporphy-
rin. Total faecal porphyrin was determined äs the sum of
the individual fractiöns. Erythrocyte porphyrin was assayed
according to Piomelli (22).
Results
Biochemical
As evident from table l, the propositus excreted large
amounts of 5-aminolaevulinic acid and coproporphy-
rin in the urine, while the concentration of porphobil-
inogen was only slightly elevated. Faeces were investi-
gated twice. On one occasion the concentration of
porphyrin was normal, on the other moderately in-
creased amounts were found, with significantly in-
creased coproporphyrin, suburopprphyrin and por-
phyrin migrating in thin layer chromatography äs
a 3-carboxylated variety, the latter dominating the
analytical picture. The concentration of erythrocyte
porphyrin was considerably increased.
The activity of aminolaevulinate dehydratase was not
restored by the addition of dithiothreitol (10~3 mol/1)
or by zinc or manganese (lO"1 —10~7 mol/l) alone or
in cornbination.
The activity of erythrocyte porphobilinogen deami-
nase of the propositus was found to be higher than
can be iriferred from the values of the grandparents,
pareüts and siblings. The urine of the proband did
not contain any substance capable of inhibiting the
enzyme in an haemolysate from a normal person. One
of the sisters, both parents and the two grandfathers
exhibited erythrocyte aminolaevulinate dehydratase
activities less than 52 per cent of the average normal
for the age group (tab. 1). Although this is not unique,
very few of the 880 presumably normal individuals
investigated had enzyme values in this ränge of the
distribution (flg. 3). The parents of the proband,
with erythrocyte enzyme activities of 35 per cent
of normal, were investigated with regard to kinetic
characteristics of the enzyme. The activities followed
Michaelis-Menten kinetics (fig. 4) and gave Km values
similar to that determined for the enzyme of a normal
relative. As'expected, differing maximal velocities
were recorded for the enzyme, being 55 — 60 per cent
of normal. In the case of the relatives with low amino-
laevulinate dehydratase activities (the two parents,
one sister, the maternal grandfather), additions of
dithiothreitol, zinc and manganese ions in the assay
C S J L m m o l / U
9.22 7.25
6.32
l 2 3 4 5 0 7 8 9 1 0
CS5 mmolj
Fig. 4. Effect on aetivity of aminolaevulinate dehydratase of varying the concentration of 5-aminolaevulinic acid, in haemolysates
ffom two individuals with decreased erythrocyte enzyme activity (© and ®) and from one person with normal activity
of the enzyme (©). For explanation of the numerical symbols see table 1.
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gave rise to slight increases of the recorded enzyme
activities, of the same magnitude s in persons with
normal enzyme activities (fig. 5). Also the patterns
of enzyme Inhibition at higher zinc and manganese
concentrations, and the partial reversal of this Inhibi-
tion by dithiothreitol, are the same for enzyme defi-
cient persons and normals.
Two of the individuals with normal erythrocyte
aminolaevulinate dehydratase activities, i.e. the pa-
ternal grandmother and the brother of the propositus,
exhibit slightly elevated porphobilinogen concentra-
tions in the urine (tab. 1). The oldest sister, who has
the highest erythrocyte aminolaevulinate dehydratase
activity of all the relatives, has a lower borderline
activity of red cell porphobilinogen deaminase. With
the exception of the propositus, and the younger of
the two sisters who shows a slight increase in the
concentration of porphyrin in the urine, none of the
individuals with decreased activities of aminolaevuli-
nate dehydratase shows evidence of any metabolic
disturbances in the haem synthetic chain.
Results of treatment
The main metabolic abnormalities in the patient, e. g.
the massive urinary excretion of 5-aminolaevulinic
acid and coproporphyrin, were present during the
whole clinical course described above. Parenteral ad-
ministration of glucose (5 g/d · kg body weight), did
not alter this excretion, nor were the neurological
Symptoms alleviated. Two courses of haematin treat-
ment were given. One of these is shown in figure 6.
The excretion decreased somewhat during the first
days of treatment but then increased again during
the course. Coproporphyrin excretion was even in-
creased. In the second course of haematin, given some
months later, no response at all in the excretion of 5-
aminolaevulinic acid was seen (not shown). Figure 7
shows the metabolic response to haem-arginate. The
excretion of 5-aminolaevulinic acid and copropor-
phyrin did not decrease but rather showed a tendency
to increase, and the Symptoms were not influenced.
In addition, the patient has, with some benefit, been
treated with physiotherapy and Splints to counteract
muscular atrophy and contractures.
Discussion
At first, the diagnosis of porphyria was not consi-
dered. The post-natal asphyxia, respiratory failure
and muscular paralysis combined with the electro-
myographic findings of total axonal degeneration
were consistent with diagnoses such s progressive
spinal muscular atrophy, congenital Guillain-Barre
syndrome or toxic neuropathy. Manifestations of the
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Fig. 5. Effects on activity of aminolaevulinate dehydratase of varying the concentrations of zinc and manganese ions, respectively,
alone and in combination with dithiothreitol (10~3 mol/1). Solid lines connect observations from assays with dithiothreitol
added. The Symbols © and © indicate haemplysates from persons with normal erythrocyte aminolaevulinate dehydratase
activity; ©, ©, ©, and © haemolysates from individuals with decreased enzyme activity (tab. 1).
pZn, pMn = — log 10 of Zn2+, Mn2+ concentration.
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Fig. 6. Urinary excretion of 5-aminolaevulinic acid and copro-
porphyrin during a 6-day-course of Panhematin treat-
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Fig. 7. rinary excretion of 5-aminolaevulinic acid and <
porphyrin during a 4-day-co rse pf haem-arginate treat-
ment (3 mg/kg BW daily) in aminolaevulinate dehydra-
tase porphyria.
hood. Clinical attacks of acute intermittent porphyria
in children have been described but are exceptional
(23). The Symptoms and signs of variegate porphyria
Start after puberty. The same is generally the case for
hereditary coproporphyria. Also in the two cases
of aminolaevulinate dehydratase porphyria hitherto
described the Symptoms first appeared in adolescence.
In no instance has acute hereditary porphyria been
diagnosed in a symptomatic neonate.
The clinical course of the proband, characterized by
remissions and exacerbations of irritability, anorexia
and polyneuropathy, however, prompted us to inves-
tigate the porphyrin metabolism. The findings of a
heavy excretion of 5-aminolaevulinic acid and of co-
proporphyrin, but only a slight increase of urinary
porphobilinogen, increased erythrocyte porphyrin
concentration and depressed activity of erythrocyte
aminolaevulinate dehydratase suggested lead intox-
ication (tab. 1). On the other hand, no exposure to
heavy metals could be shown, and urinary and whole
blood levels of lead were normal. Further, the activity
of the enzyme could neither be restored by a thiol
reagent such s dithiothreitol, nor by zinc or
manganese ions, so an explanation other than heavy
metal intoxication had to be found. The possibility
of Inhibition of the enzyme by succinylacetone, which
is produced in hereditary tyrosinaemia, was consi-
dered, but metabolic screening excluded that disease
and the urine did not contain any substance capable
of inhibiting aminolaevulinate dehydratase activity,
s in tyrosinaemia (8). Since the prevalence of acute
intermittent porphyria in Sweden is high, the activity
of erythrocyte porphobilinogen deaminase was inves-
tigated in the proband s well s in the rest of the
blood relatives. As evident fr m table l the activity
of this enzyme in the proband was found to be in the
upper borderline region, which might be a reflection
of the presence in the blood of immature red cell
elements. With the exception of one of bis sisters
(No. 7, tab. 1), who exhibited a lower borderline level,
all the relatives had normal values. No evidence for
the occurrence of acute intermittent porphyria in the
kindred could Ums be obtained. Further, the excre-
tion patterns of porphyrins and porphyrin precursors
in the proband and the findings of elevated erythro-
cyte porphyrin were not consistent with this condi-
tion.
Investigation of the family, on the other hand, re-
vealed that several of the members through three
generations had erythrocyte aminolaevulinate dehy-
dratase activities below 50 per cent of normal. In
humans the activity of aminolaevulinate dehydratase
is under genetic influence (23), the enzyme probably
being under the control of an autosomal gene with
two different alleles (24, 25) located on chromosome
9 (26). The activity of the enzyme shows wide Varia-
tion in a reference population, which is evident in
figure 3, and activities below 50 per cent of the
average normal are encountered also in a few presum-
ably normal individuals. Nevertheless, the avail ble
evidence indicates that the disposition of the amino-
laevulinate dehydratase gene differs from normal in
the kindred in questioii. In 1979 Bird et al. (28)
reported a family with inherited deficiency of amino-
laevulinate dehydratase, encountered during a popu-
lation study. The enzyme deficiency occurred through
three generations in an autosomal dominant pattern.
The enzyme activities recorded in the red cells of the
affected individuals ranged between 22 and 41 per
·
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cent of normal. In no instance did clinical or bio-
chemical Symptoms accompany the deficiency. In the
same year Doss et al. described two patients with
acute porphyria whose Symptoms first appeared in
adolescence and were associated with a severe de-
crease in aminolaevulinate dehydratase activity. Fur-
ther investigations of the patients and their families
have provided evidence of a structural mutation of
the gene encoding the enzyme, with production of a
noncatalytic protein. Clinical manifestations oc-
curred in the two apparently homozygous patients
but not in their presumably heterozygous relatives (l,
29, 30, 31). Our index patient differs from those
described by Doss et al. by exhibiting severe
Symptoms from birth, but nevertheless the Symptoms
were typical of acute porphyria. The biochemical
profile resembles that in Doss7 patients, i. e., massive
excretion of 5-aminolaevulinic acid, modest increase
of the porphobilinogen concentration in urine, heavy
coproporphyrinuria, elevated erythrocyte porphyrin
concentration and very low aminolaevulinate dehy-
dratase activity in the red blood cells. On one occa-
sion analyses of faecal excretion of porphyrins were
normal. During a clinical exacerbation, however, the
concentration of porphyrin in faeces increased, yield-
ing a thin layer chromatography pattefn reminiscent
of that seen in harderoporphyria (32). The observa-
tions thus strongly suggest that the proband is homo-
zygous for a defective aminolaevulinate dehydratase-
controlling gene.
A study of the pedigree gives support to this assump-
tion (fig. 2). One of the sisters, the two parents and
both the grandfathers, all healthy, have erythrocyte
enzyme activities ranging between 26 and 51 per cent
of the average normal for their respective age groups.
These findings mdicate that they are asymptoinatic
heterozygous carriers. The study of aminolaevulinate
dehydratase kinetic parameters of the parents did not
disclose any deviatiöns from normal with regafd to
Substrate affinity of the enzyme (tab. 1). The values
obtained for Km are slightly lower than those reported
for normal individüals in öther Communications (28,
31, 33), discrepancies which might be due to differen-
ces in environmental lead pressure betweeii the popu-
lations in questions (31, 34). Nor were any significant
differences found when zinc, mänganese and dithio-
threitol activation of the enzyme was compared be-
tween the heterozygotes and the nonaffected indivi-
duals in the kindred. Taken together, the observations
imply that the index case belongs to a family with
aminolaevulinate dehydratase deficiency, inherited
through three generations in an autosomal dominant
mode. The condition appears to depend on a muta-
tion leading either to abolished enzyme synthesis or
to the synthesis of an inactive enzyme. In the hetero-
zygous state it seems to be without obvious pathologi-
cal significance for the individual, but in homozygous
form it gives rise to severe porphyric Symptoms. As in
the previously studied family with aminolaevulinate
dehydratase porphyria (29), the disorder in the pre-
sent family follows the general scheine of an autoso-
mal reeessive disease (37).
Apart from the different age of onset, the present
case differs in some other important aspects com-
pared with the two patients described by Doss et al.
In addition to the neurological Symptoms, the patient
also has signs of a mild haemolytic state with in-
creased reticulocyte counts and marked bone marrow
erythropoietic activity. Thus our patient seems not
to have a pure hepatic form of porphyria, since there
is also evidence for an erythropoietic component. The
response to treatment also differs from the experience
ofDoss et al. In contrast to them we saw no beneficial
effects of concentrated glucose infusion. The findings
might indicate an even more severe enzyme deficiency
in our case.
In acute intermittent porphyria haematin or haem-
arginate treatment is often effective in inducing a
clinical remission accompanied by a decrease in the
excretion of 5-aminolaevulinic acid and porphobilin-
ogen. Haem infusions are believed to increase the
free haem pool of the liver cells and thereby cause a
feed-back Inhibition of aminolaevulinate synthase.
We noticed no consistent effect of haem in our case
of aminolaevulinate dehydratase porphyria. No ex-
planation for this can be offered at the moment,
but perhaps haem oxygenase was induced by the
administered haem. This would lead to accelerated
haem degradation and a diminished free regulatory
haem pool.
The question of how haem synthesis is maintained
under circumstances of a practically total block of
one of the Steps in the pathway presents an intriguing
problem in the present case äs well äs in other forms
of homozygous porphyria. A common denominator
for these conditions seems to be overload of the
erythroid ferrochelatase Step, äs evidenced by accu-
mulation of protoporphyrin in the red blood cells.
This is the case in congenital erythropoietic porphyria
(36), in hepatoerythropoietic porphyria (37, 38), vari-
egate porphyria (39), and harderoporphyria (32) äs
well äs in the previously reported cases of aminola-
evulinate dehydratase porphyria (1). In the present
case, a metabolic overflow also seems to occur at the
coproporphyrinogen oxidase Step, äs indicated by
the increased excretion of coproporphyrin and 3-
carboxylated porphyrin. The metabolic significance
of these observations remains to be elucidated.
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As can be noted in figure 3, activities of aminolaevuli-
nate dehydratase below 50 per cent of normal are
not exceptional in the population, being found in 16
out of the 880 persons investigated. If these indivi-
duals are heterozygous carriers of äminolaevulinate
dehydratase deficiency, the pfevalence of this condi-
tion is about 2 per cent. The implications are of
obvious practical importance since a gene frequency
of this magnitude will lead to a significant number
of marriages between heterozygotes and generation
of individuals homozygous in the condition. The fact
that the mother of the patient reported in the present
communication had four spontaneous abortions may
indicate that the homozygous deficiency of äminolae-
vulinate dehydratase usually is not compatible with
life, and that the few cases of the disorder observed
represent rare exceptions from this rule. Pirobably it
would be useful to routinely investigate paternal and
maternal erythrocyte aminolaevulinate dehydratase
activities in cases of habitual abortions. Work is in
progress to evaluate this proposal.
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